New meta-analysis shows that pirfenidone in idiopathic pulmonary fibrosis (IPF) may provide dual protection: (1) slowing fibrosis progression, and (2) reducing lung cancer risk. Pirfenidone's impact on cough as a key symptom in patients with IPF is yet to be measured objectively.

Published 4 hours ago
Source: reddit.com

Categories

science